Thalidomide-O-amido-C3-COOH

Background Introduction

Thalidomide-O-amido-C3-COOH is an advanced E3 ligase ligand-linker conjugate designed for use in proteolysis targeting chimera (PROTAC) research. This compound combines a thalidomide-derived E3 ligase ligand with a C3 alkyl linker that terminates in a carboxyl group, enabling efficient conjugation to a variety of target protein ligands. As PROTAC technology continues to gain prominence in targeted protein degradation, high-quality E3 ligase ligand-linker intermediates like Thalidomide-O-amido-C3-COOH have become essential tools for drug discovery and functional genomics.

Mechanism

Thalidomide-O-amido-C3-COOH works by leveraging the cellular ubiquitin-proteasome system. When incorporated into PROTACs, the thalidomide moiety specifically binds to the cereblon (CRBN) E3 ubiquitin ligase, while the carboxy-terminated linker allows for chemically attaching a ligand that recognizes the protein of interest. Upon binding both the E3 ligase and the target protein, the resulting PROTAC induces the ubiquitination and subsequent proteasomal degradation of the target protein, offering a catalytic mechanism to remove disease-associated proteins from cells.

Applications

Thalidomide-O-amido-C3-COOH is widely utilized in the development of PROTAC molecules for targeted protein degradation. Researchers can use this E3 ligase ligand-linker intermediate to quickly synthesize new PROTACs aimed at degrading a wide range of proteins, accelerating preclinical drug development and mechanistic studies. Its versatile design enables the generation of diverse PROTAC libraries, facilitating high-throughput screening for novel therapeutics in cancer, neurodegenerative disorders, and other protein dysfunction-related diseases.

• Carboxylic acid-terminated linker enables versatile coupling to target ligands or payloads for PROTAC development.
• Designed for efficient and selective CRBN E3 ligase recruitment in targeted protein degradation applications.

Thalidomide-O-amido-C3-COOH serves as a versatile E3 Ligase Ligand-Linker Conjugate in PROTACs, enhancing targeted protein degradation by bridging target proteins with E3 ligases. This molecule's design facilitates efficient protein degradation, offering a strategic advantage in drug discovery and research applications. The following provides a detailed description of this molecule.

Linker: This molecule features a C3 linker, characterized by its moderate length and flexible nature, allowing for optimal spatial arrangement between the ligand and target protein. The linker is non-cleavable, providing stability and ensuring sustained interaction with the target.

Ligand: The ligand component of this molecule is derived from thalidomide, known for its high affinity to cereblon, an E3 ubiquitin ligase. Its structural configuration supports efficient binding, playing a crucial role in the targeted protein degradation pathway.

Reactive Site: The reactive site in this molecule is the carboxylic acid group, which couples efficiently with amine groups on the target protein ligand. Recommended reaction types include amide bond formation, which is a robust method for conjugating the ligand to a variety of target proteins.

Recommended Target Protein Ligand: The molecule is compatible with warheads featuring primary or secondary amines, which facilitate strong covalent bond formation through amide linkage. This compatibility allows for the development of highly specific and potent PROTACs, enabling precise degradation of target proteins, which is invaluable in research focused on understanding protein function and in drug development.